TQ05105
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Hemophagocytic LymphohistiocytosisMass Balance of [14C] TQ05105 in Healthy Chinese SubjectsMyelofibrosisMyeloproliferative Neoplasms
Phase 1
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
NCT04326348
Start: 2020-07-17End: 2022-07-31Target: 40Updated: 2020-09-10
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
CompletedNCT04339400
Start: 2018-11-20End: 2023-03-17Updated: 2026-06-03
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
CompletedNCT06598956
Start: 2024-10-12End: 2025-08-12Updated: 2025-08-24
A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
CompletedNCT07293390
Start: 2024-03-18End: 2024-08-20Updated: 2025-12-19
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
RecruitingNCT07480824
Start: 2026-04-01End: 2026-12-01Target: 24Updated: 2026-04-06